| study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic head and neck cancer previously treated with platinum-based chemotherapy | Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based chemotherapy (study L00070 IN 309 F0) - NA | EUCTR2011-005081-38-DE |
| A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant. | A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant. | PER-079-10 |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer | Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination | NCT01529411 |
| - | Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract. - JASiMA - JAVLOR Switch in Maintenance | EUCTR2011-000272-34-DE |
| Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium | Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium - JASINT 1 | NL-OMON36397 |
| Pazopanib and Vinflunine in Urothelial Cancer of the Bladder | Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment | NCT01265940 |
| A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy - VINCENT | A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive Cisplatin-Based Therapy - VINCENT | EUCTR2005-003733-40-FR |
| Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium | Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium | EUCTR2010-020620-22-FR |
| Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract | NCT00315237 |
| A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER | A PHASE III RANDOMIZED CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERSUS PACLITAXEL, DOCETAXEL OR VINFLUNINE IN SUBJECTS WITH RECURRENT OR PROGRESSIVE METASTATIC UROTHELIAL CANCER | PER-074-14 |
| Effect of Ketoconazole on the Pharmacokinetics of Vinflunine | Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer | NCT00388557 |
| A Study of the Alternative Administration of Ixabepilone and Vinflunine | A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer | NCT00362830 |
| A Study of Vinflunine in Patients With Gastric Cancer | A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer | NCT00359476 |
| Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors | A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors | NCT00320073 |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT01599013 |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium | NCT00101608 |
| Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer | NCT00284154 |
| Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer | NCT00284180 |
| A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the UrotheliumRevised Protocol #01, version 2.0 incorporating Protocol Amendment #04, andPharmacogenetics Blood Sample Amendment #01, dated 18-Oct-04Primary Tumor Tissue Sample Amendment #02, dated 18-Oct-04Pharmacokinetics Blood Sample Amendment #03, dated 18-Oct-04 | A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the UrotheliumRevised Protocol #01, version 2.0 incorporating Protocol Amendment #04, andPharmacogenetics Blood Sample Amendment #01, dated 18-Oct-04Primary Tumor Tissue Sample Amendment #02, dated 18-Oct-04Pharmacokinetics Blood Sample Amendment #03, dated 18-Oct-04 | EUCTR2005-001463-64-AT |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy | NCT00389155 |
| A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer | A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer | NCT00251446 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract | NCT01844947 |
| Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0) | Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0) | EUCTR2009-011118-47-FR |
| MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer | A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer - MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer | EUCTR2014-002009-40-BE |
| A randomised study of cabazitaxel versus vinflunine in bladder carcinoma. | A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium - Cabazitaxel vs. vinflunine in metastatic or locally advanced TCCU | EUCTR2012-002826-55-ES |
| Ensayo clínico en fase III de vinflunina más capecitabina frente a sólo capecitabina en pacientes con cáncer de mama avanzado previamente tratados con o resistentes a una antraciclina y que sean resistentes a taxanosA phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant | Ensayo clínico en fase III de vinflunina más capecitabina frente a sólo capecitabina en pacientes con cáncer de mama avanzado previamente tratados con o resistentes a una antraciclina y que sean resistentes a taxanosA phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant | EUCTR2008-004171-21-ES |
| A phase II - III double-blind study of oral vinflunine plus best supportive care versus placebo plus best supportive care in patients with malignant pleural mesothelioma previously treated with systemic chemotherapy. | A phase II - III double-blind study of oral vinflunine plus best supportive care versus placebo plus best supportive care in patients with malignant pleural mesothelioma previously treated with systemic chemotherapy. | EUCTR2008-003196-48-FR |
| Vinflunine in Hormone Refractory Prostate Cancer (HRPC) | A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC) | NCT00545766 |
| A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapy | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer | EUCTR2020-002964-29-BE |
| A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer | Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer | NCT00534807 |
| Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC | Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer | NCT00519831 |
| Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer | Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer | NCT00450515 |
| A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Participants with Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations | JPRN-jRCT2080223892 |
| Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer | Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer - JaNEO | EUCTR2016-000081-33-DE |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function | A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function. | NCT02665039 |
| A study to compare study medication Sacituzumab Govitecan with Standardof Care medications (Paclitaxel, Docetaxel or Vinflunine) in Metastatic (spread to other locations in the body) or Locally Advanced Unresectable (cannot be removed surgically) Urothelial (urinary system) Cancer which has progressed or returned after prior treatments with platinum containing chemotherapy and immunotherapy | A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer | EUCTR2020-002964-29-IE |
| Phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic bladder cancer. | Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma. - Jasint-2 | EUCTR2014-005396-82-ES |
| A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer (VICTORIA) | Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy | PER-057-07 |
| A comparative study between two different chemotherapy treatments for patients with metastatic bladder cancer and renal impairment | A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based chemotherapy due to impaired renal function. - NUCOG I-VINGEM | EUCTR2013-002417-35-SE |
| A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium | A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium - Cabazitaxel vs. vinflunine in metastatic or locally advanced TCCU | NL-OMON38902 |
| study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic head and neck cancer previously treated with platinum-based chemotherapy | Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based chemotherapy (study L00070 IN 309 F0) - NA | EUCTR2011-005081-38-BE |
| A Phase II Trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis (VinCaP) | A Phase II Trial of Vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis - VinCaP | EUCTR2012-002592-34-GB |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | A Multicenter, Randomised, Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously | NCT01953003 |
| study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic head and neck cancer previously treated with platinum-based chemotherapy | Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based chemotherapy (study L00070 IN 309 F0) - NA | EUCTR2011-005081-38-IT |
| Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer | Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy | NCT02347332 |
| A clinical trial to compare the effects of two chemotherapy regimens (vinflunine plus capecitabine versus capecitabine alone) in patients with advanced breast cancer. | A phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant - L00070 IN 305 B0 | CTRI/2009/091/000607 |
